Generic Medicine Info
Indications and Dosage
Tardive dyskinesia
Adult: Initially, 40 mg once daily for 1 week, increased to 80 mg once daily. Consider continuation of 40 mg once daily dose based on patient response and tolerability.
Special Patient Group
Patients taking strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, clarithromycin): Reduce maintenance dose to 40 mg once daily.

Patients taking strong CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin): Not recommended.

Patients taking strong CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, quinidine): Consider dose reduction based on patient tolerability.


Valbenazine is metabolised to its active metabolite, (+)-α-HTBZ, via hydrolysis of valine ester. (+)-α-HTBZ is further metabolised in part by CYP2D6.

Patients who are CYP2D6 poor metabolisers or concomitantly taking strong CYP2D6 inhibitors may have increased serum concentrations of valbenazine and (+)-α-HTBZ active metabolite thereby may increase risk of adverse effects (e.g. QT prolongation). The FDA-approved drug label recommends considering dose reduction for patients who are known CYP2D6 poor metabolisers based on tolerability.
Renal Impairment
 CrCl (mL/min) Dosage 
 <30  Not recommended.
Hepatic Impairment
Moderate to severe (Child-Pugh score 7-15): 40 mg once daily.
cap: May be taken with or without food.
Patients with congenital long QT syndrome or arrhythmias associated with prolonged QT interval. Concomitant use with MAOIs (e.g. isocarboxazid, phenelzine, selegiline).
Special Precautions
CYP2D6 poor metabolisers. Severe renal and moderate to severe hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Prolonged QT interval, Parkinson-like symptoms (e.g. falls, gait disturbances, tremor, drooling, hypokinesia), somnolence, hypersensitivity reactions (e.g. allergic dermatitis, angioedema, pruritus, urticaria).
Eye disorders: Blurred vision.
Gastrointestinal disorders: Dry mouth, constipation, vomiting, nausea.
General disorders and administration site conditions: Fatigue, balance disorder.
Investigations: Increased blood glucose, increased weight.
Musculoskeletal and connective tissue disorders: Arthralgia.
Nervous system disorders: Sedation, dyskinesia, dizziness, headache, extrapyramidal symptoms (non-akathisia).
Psychiatric disorders: Akathisia, restlessness, anxiety, insomnia, disturbance in attention.
Renal and urinary disorders: Urinary retention.
Respiratory, thoracic and mediastinal disorders: Respiratory infections.
Patient Counseling Information
This drug may cause somnolence, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor for signs of involuntary movement or Parkinson-like symptoms. Perform ECG prior to increasing dose in patient at risk of QT prolongation.
Drug Interactions
Increased risk of adverse effects with strong inhibitors of CYP2D6 (e.g. paroxetine, fluoxetine, quinidine) or CYP3A4 (e.g. itraconazole, ketoconazole, clarithromycin). May reduce efficacy of valbenazine with strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin). Increased serum concentration of P-glycoprotein substrates (e.g. digoxin).
Potentially Fatal: Increased risk of adverse effects (e.g. serotonin syndrome) of MAOIs (e.g. isocarboxazid, phenelzine, selegiline).
Food Interaction
Decreased serum concentrations of valbenazine with St. John’s wort and high-fat food.
Description: Valbenazine reversibly inhibits the vesicular monoamine transporter 2 (VMAT2) which regulates the uptake of monoamine from the cytoplasm to the synaptic vesicle for storage and release. It has no binding affinity for VMAT1 nor the dopaminergic, serotonergic, adrenergic, histaminergic or muscarinic receptors.
Absorption: Bioavailability: Approx 49%. Time to peak plasma concentrations: 0.5-1 hour (valbenazine); 4-8 hours (active metabolite). Decreased serum concentration with high fat meal.
Distribution: Volume of distribution: 92 L. Plasma protein binding: >99% (valbenazine); approx 64% (active metabolite).
Metabolism: Extensively metabolised via hydrolysis of valine ester to active metabolite, (+)-α-dihydroxytetrabenazine [(+)-α-HTBZ] and via oxidative metabolism by CYP3A4/5 to mono-oxidised valbenazine and other minor metabolites. (+)-α-HTBZ is further metabolised in part by CYP2D6.
Excretion: Via urine (approx 60%, mainly as inactive metabolites; <2% as unchanged drug or active metabolite); via faeces (30%, mainly as inactive metabolites; <2% as unchanged drug or active metabolite). Elimination half-life: 15-22 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Valbenazine, CID=24795069, (accessed on Jan. 23, 2020)

Store below 30°C.
MIMS Class
Neuromuscular Disorder Drugs
ATC Classification
N07XX13 - valbenazine ; Belongs to the class of other nervous system drugs.
Uhlyar S, Rey JA. Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia. Drug Forecast. 2018 Jun;43(6):328-331. Accessed 17/10/2019

Annotation of FDA Label for Valbenazine and CYP2D6. Pharmacogenomics Knowledgebase (PharmGKB). Accessed 17/10/2019.

Anon. Valbenazine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 17/10/2019.

Buckingham R (ed). Valbenazine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/10/2019.

Ingrezza (Neurocrine Biosciences, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 17/10/2019.

Ingrezza (Neurocrine Biosciences, Inc.). U.S. FDA. Accessed 17/10/2019.

Disclaimer: This information is independently developed by MIMS based on Valbenazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in